NZX Governance Explorer

How Promisia Healthcare Limited makes money

Where PHL’s revenue went in FY2023: operating costs, depreciation, interest and tax, and what was left as net profit. Built from the income statement in the filed annual report, and drawn only when the figures reconcile with each other. PHL company profile

How Promisia Healthcare Limited makes money — FY2023

Revenue $23.9m · EBITDA $3.6m (15.0% of revenue) · Net profit $692k (2.9% of revenue) · Financial year ending March (from the issuer record)

Promisia Healthcare Limited (PHL) FY2023: where revenue of $23.9m wentRevenue → EBITDA: $3.6mRevenue → Operating expenses: $20.3mEBITDA → EBIT: $2.7mEBITDA → Depreciation & amortisation: $838kEBIT → Net profit: $692kEBIT → Interest: $2.1mIncome tax credit → Interest: $92kOther items (net gain) → Interest: $137kRevenue: $23.9mRevenue$23.9mEBITDA: $3.6mEBITDA$3.6mOperating expenses: $20.3mOperating expenses$20.3mEBIT: $2.7m (derived)EBIT$2.7m · derivedDepreciation & amortisation: $838kDepreciation &amortisation$838kIncome tax credit: $92kIncome tax credit$92kOther items (net gain): $137k (balancing item)Other items (net gain)$137k · balancingNet profit: $692kNet profit$692kInterest: $2.3mInterest$2.3m

Band widths are proportional to NZD amounts. Dashed outlines mark derived figures; the hatched node is a balancing item (net profit less every line above it).

Promisia Healthcare Limited FY2023 figures used in the chart
FY2023AmountStatusNote
Revenue$23.9mReported
Operating expenses−$20.3mReported
EBITDA$3.6mReported
Depreciation & amortisation−$838kReported
EBIT$2.7mDerived *Reported EBIT $3.6m does not reconcile to EBITDA − D&A.
Interest (net finance costs)−$2.3mReported
Income tax credit+$92kReported
Other items (net gain)+$137kBalancing item *Net profit less the lines above; covers fair-value movements, impairments, associates and anything else not itemised.
Net profit$692kReported
  • * ebit: $2.7m = EBITDA − D&A (reported EBIT $3.6m differs; the gap falls into Other items)
Checks run on these figures (6)
  • Passed: Revenue is within the scale of a column stored in thousands.
  • Passed: Revenue in the income statement ($23.9m) vs the summary table ($23.9m): agree within 2%.
  • Not met: EBITDA − D&A = $2.7m vs reported EBIT $3.6m: does not reconcile.
  • Passed: Revenue − operating expenses = $3.6m, reconciles to EBITDA $3.6m.
  • Passed: Balancing item $0.1m is 0.6% of revenue (limit 25%).
  • Not met: No operating segments recorded for this year.

Figures extracted automatically from the annual report; check against the report. NZD thousands as stored, shown in millions. Source: annual_report_pdf · method: claude_haiku_pdf · extracted 7 March 2026.

Annual report: FY23 Promisia Annual Report (PDF, NZX)

EBITDA bridge, FY2022 → FY2023

What moved EBITDA between the two years: the change in revenue, less the change in operating costs (revenue less EBITDA, net of other income; not a reported line). The costs are one net figure; no split by type is held, so none is shown.

PHL EBITDA bridge FY2022 to FY2023FY2022 EBITDA: $4.5m$4.5mFY2022 EBITDARevenue change: +$4.9m+$4.9mRevenue changeCost change (derived): −$5.8m−$5.8mCost change (derived)FY2023 EBITDA: $3.6m$3.6mFY2023 EBITDA
PHL EBITDA bridge FY2022 to FY2023: figures
StepFY2022FY2023Effect on EBITDAStatus
FY2022 EBITDA$4.5m$4.5mAs charted
Revenue$19.0m$23.9m+$4.9mReported
Operating costs (net, derived)$14.5m$20.3m−$5.8mDerived: revenue − EBITDA
FY2023 EBITDA$3.6m$3.6mAs charted

$4.5m +$4.9m −$5.8m = $3.6m, which equals FY2023 EBITDA of $3.6m. EBITDA is the figure stored from each statement; companies that headline an adjusted measure (EBITDAF, underlying EBITDA) can report a different number.

What changed from FY2022 to FY2023

MeasureFY2022FY2023ChangeChange %
Revenue$19.0m$23.9m+$4.9m+25.7%
EBITDA$4.5m$3.6m−$918k−20.4%
Net profit$2.0m$692k−$1.3m−65.9%
EBITDA margin23.7%15.0%−8.7 pts—
Net margin10.7%2.9%−7.8 pts—

Both years passed the same checks. Margins are shares of revenue; their change is in percentage points. n/m = not meaningful (prior-year figure at or below zero). Each year holds the figures from its own annual report; restated comparatives are not applied.

Margins over time

EBITDA, EBIT and net profit as a share of revenue for each year whose figures passed the checks (5 of 9 years from FY2017). The shaded line is the median of 11 other listed Healthcare operating companies, using each one’s same financial year where it passed the checks; the number of companies in each median is in the table. Gaps are years that were not charted.

EBITDA margin
PHL ebitda margin by financial year, with peer median0%20%40%FY17FY18FY20FY22FY24FY25FY2017: not charted — operating lossFY2018: not charted — operating lossFY2019: not charted — operating lossFY2020: not charted — no annual statement on fileFY2021: PHL 16.8%; peer median 19.1% (3)FY2022: PHL 23.7%; peer median 22.4% (4)FY2023: PHL 15.0%; peer median 11.4% (5)FY2024: PHL 13.8%; peer median 12.2% (7)FY2025: PHL 13.5%; peer median 13.2% (7)
EBIT margin
PHL ebit margin by financial year, with peer median0%20%40%FY17FY18FY20FY22FY24FY25FY2017: not charted — operating lossFY2018: not charted — operating lossFY2019: not charted — operating lossFY2020: not charted — no annual statement on fileFY2021: PHL 10.5%; peer median 9.5% (5)FY2022: PHL 19.4%; peer median 18.3% (4)FY2023: PHL 11.5%; peer median 6.9% (5)FY2024: PHL 10.8%; peer median 6.4% (7)FY2025: PHL 12.2%; peer median 8.8% (7)
Net margin
PHL net margin by financial year, with peer median0%20%40%FY17FY18FY20FY22FY24FY25FY2017: not charted — operating lossFY2018: not charted — operating lossFY2019: not charted — operating lossFY2020: not charted — no annual statement on fileFY2021: PHL 0.4%; peer median 3.7% (5)FY2022: PHL 10.7%; peer median 13.7% (4)FY2023: PHL 2.9%; peer median 6.2% (5)FY2024: PHL 6.2%; peer median 3.1% (7)FY2025: PHL 22.0%; peer median 5.5% (7)

PHL   peer median   below the axis: year not charted (reason in the table). All panels share one scale.

PHL margins by year with peer medians
YearEBITDA margin: PHL · peer median (n)EBIT margin: PHL · peer median (n)Net margin: PHL · peer median (n)Note
FY2017—— (1)—33.0% (2)—22.5% (2)Not charted: operating loss
FY2018—8.6% (3)—16.6% (4)—11.6% (4)Not charted: operating loss
FY2019—11.7% (4)—7.2% (5)—3.9% (5)Not charted: operating loss
FY2020—9.3% (4)—12.8% (6)—7.9% (6)Not charted: no annual statement on file
FY202116.8%19.1% (3)10.5%9.5% (5)0.4%3.7% (5)
FY202223.7%22.4% (4)19.4%18.3% (4)10.7%13.7% (4)
FY202315.0%11.4% (5)11.5%6.9% (5)2.9%6.2% (5)
FY202413.8%12.2% (7)10.8%6.4% (7)6.2%3.1% (7)
FY202513.5%13.2% (7)12.2%8.8% (7)22.0%5.5% (7)

Peer medians use only peer-years that passed the same checks; a median of fewer than two companies is not shown. Years are grouped by financial-year label, and year-end months differ between companies.

Not yet available: where the cash goes (operating cash flow to capex, dividends and debt) and underlying versus reported earnings. The figures they need are not yet validated.

Years not charted

These years are on file but their figures did not pass the checks, so no chart is drawn for them.

  • FY2019: EBIT is -$1.7m. This layout does not draw an operating loss.
  • FY2018: EBITDA is -$2.3m. This layout draws revenue flowing into profit and does not draw an operating loss.
  • FY2017: EBITDA is -$0.4m. This layout draws revenue flowing into profit and does not draw an operating loss.
  • FY2016: EBITDA is -$0.4m. This layout draws revenue flowing into profit and does not draw an operating loss.
  • FY2015: Figures were not read from a filed annual report (source: not recorded).

All companies with a chart

Data sourced from NZX company annual reports (income statements). Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz.

For informational purposes only. Not investment advice.

Get NZX governance insights in your inbox

Weekly digest of board changes, insider trades, and market signals. No spam. Unsubscribe anytime.